MorphoSys appoints Wendy Johnson, Klaus Kühn and Dr. Frank Morich to its Supervisory Board

– GERMANY, Munich – MorphoSys AG (FSE: MOR) announced today that its shareholders elected Ms. Wendy Johnson, Mr. Klaus Kühn and Dr. Frank Morich as new members of the Supervisory Board. Dr. Gerald Möller, Dr. Marc Cluzel and Ms. Karin Eastham were re-elected as Supervisory Board Members.

“We are pleased to announce the new election of Ms. Wendy Johnson, Mr. Klaus Kühn and Dr. Frank Morich, three highly qualified industry experts, and look forward to working with them,” commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG. “On behalf of the Management Board and the Company, I would like to thank the resigning Supervisory Board Members Dr. Walter Blättler, Dr. Daniel Camus and Dr. Geoffrey Vernon for their invaluable support over many years in establishing MorphoSys as a leading biopharmaceutical company.”

About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.

Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 90 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer’s disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.